Bunce C - Search Results

1

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.

Jankowski W, McGill J, Lagassé HAD, Surov S, Bembridge G, Bunce C, Cloake E, Fogg MH, Jankowska KI, Khan A, Marcotrigiano J, Ovanesov MV, Sauna ZE. Jankowski W, et al. Among authors: bunce c. Blood Adv. 2019 Sep 10;3(17):2668-2678. doi: 10.1182/bloodadvances.2019000338. Blood Adv. 2019. PMID: 31506285 Free PMC article.

2

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.

Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, Kroenke MA, Lamberth K, Manin A, Penny HL, Smith N, Terszowski G, Tourdot S, Spindeldreher S. Ducret A, et al. Among authors: bunce c. MAbs. 2022 Jan-Dec;14(1):1993522. doi: 10.1080/19420862.2021.1993522. MAbs. 2022. PMID: 34923896 Free PMC article. Review.

3

A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

Francis JN, Bunce CJ, Horlock C, Watson JM, Warrington SJ, Georges B, Brown CB. Francis JN, et al. Among authors: bunce cj. Vaccine. 2015 Jan 3;33(2):396-402. doi: 10.1016/j.vaccine.2014.06.006. Epub 2014 Jun 10. Vaccine. 2015. PMID: 24928790 Free article. Clinical Trial.

4

Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.

Watson JM, Francis JN, Mesens S, Faiman GA, Makin J, Patriarca P, Treanor JJ, Georges B, Bunce CJ. Watson JM, et al. Virol J. 2015 Feb 3;12:13. doi: 10.1186/s12985-015-0240-5. Virol J. 2015. PMID: 25645025 Free PMC article.

5

Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials.

Muller J, Parizotto E, Antrobus R, Francis J, Bunce C, Stranks A, Nichols M, McClain M, Hill AVS, Ramasamy A, Gilbert SC. Muller J, et al. Among authors: bunce c. J Transl Med. 2017 Jun 8;15(1):134. doi: 10.1186/s12967-017-1235-3. J Transl Med. 2017. PMID: 28595644 Free PMC article. Clinical Trial.

6

Development of vaccines to help treat drug dependence.

Bunce CJ, Loudon PT, Akers C, Dobson J, Wood DM. Bunce CJ, et al. Curr Opin Mol Ther. 2003 Feb;5(1):58-63. Curr Opin Mol Ther. 2003. PMID: 12669472 Review.

7

Fulfilling the promise of immunotherapy.

Bunce C, Morse MA. Bunce C, et al. Curr Opin Mol Ther. 2006 Feb;8(1):9-10. Curr Opin Mol Ther. 2006. PMID: 16506519 Review. No abstract available.

8

Priming, boosting, measuring.

Bunce CJ, Morse MA. Bunce CJ, et al. Curr Opin Mol Ther. 2002 Feb;4(1):13-4. Curr Opin Mol Ther. 2002. PMID: 11883689 No abstract available.

9

Autistic adults exhibit typical sensitivity to changes in interpersonal distance.

Bunce C, Gehdu BK, Press C, Gray KLH, Cook R. Bunce C, et al. Autism Res. 2024 Jun 3. doi: 10.1002/aur.3164. Online ahead of print. Autism Res. 2024. PMID: 38828663

10

The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK.

Bourne RRA, Moledina M, Azuara-Blanco A, Saleh GM, Self JE, Sivaprasad S, Sharma SM, Ross A, Gilbert RM, Abdalla Elsayed MEA, Moon WY, Doug M, Mulholland PJ, Day AC, Romano V, Hoad GV, Kara M, Murray A, Gow L, Ghanchi F, Patel PJ, Gale RP, Dinah C, Valentine K, Yelf C, Poustie V; NIHR Ophthalmology Specialty Group; Executive Group of UK Clinical Eye Research Strategy. Bourne RRA, et al. Eye (Lond). 2024 May 29. doi: 10.1038/s41433-024-03049-6. Online ahead of print. Eye (Lond). 2024. PMID: 38806699

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

703 results

Search Page